Active, Not Recruiting
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
NCT04300244
- Conditions
- Adenoma, Cancer, Cancer of Lung, +17 more
- Locations
-
- University of Western Australia Perth, Australia
- Aalborg University Hospital Aalborg, Denmark
- Copenhagen University Hospital Copenhagen, Denmark
- Oslo University Hospital Oslo, Norway